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Abstract
Background: Maintenance of genome integrity is crucial for the propagation of the genetic information. Cdt1 is a major
component of the pre-replicative complex, which controls once per cell cycle DNA replication. Upon DNA damage, Cdt1 is
rapidly targeted for degradation. This targeting has been suggested to safeguard genomic integrity and prevent re-
replication while DNA repair is in progress. Cdt1 is deregulated in tumor specimens, while its aberrant expression is linked
with aneuploidy and promotes tumorigenesis in animal models. The induction of lesions in DNA is a common mechanism
by which many cytotoxic anticancer agents operate, leading to cell cycle arrest and apoptosis.
Methodology/Principal Finding: In the present study we examine the ability of several anticancer drugs to target Cdt1 for
degradation. We show that treatment of HeLa and HepG2 cells with MMS, Cisplatin and Doxorubicin lead to rapid
proteolysis of Cdt1, whereas treatment with 5-Fluorouracil and Tamoxifen leave Cdt1 expression unaffected. Etoposide
affects Cdt1 stability in HepG2 cells and not in HeLa cells. RNAi experiments suggest that Cdt1 proteolysis in response to
MMS depends on the presence of the sliding clamp PCNA.
Conclusion/Significance: Our data suggest that treatment of tumor cells with commonly used chemotherapeutic agents
induces differential responses with respect to Cdt1 proteolysis. Information on specific cellular targets in response to
distinct anticancer chemotherapeutic drugs in different cancer cell types may contribute to the optimization of the efficacy
of chemotherapy.
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Introduction
Cancer is a complex, multifactorial disease with both genetic
and environmental factors involved in its etiology. Despite the
complexity, cancer cells exhibit prevailing characteristics that
distinguish them from normal cells. Genomic instability is a
hallmark of cancer cells, believed to lie at the heart of the
acquisition of new traits by cancer cells during neoplastic
development. Indeed, around 50% of all tumors exhibit gross
chromosomal abnormalities, evident as accumulation of additional
copies of genes, genomic regions or whole chromosomes as well as
chromosomal rearrangements.
Genomic instability could arise due to the loss of control
mechanisms which operate during the normal cell cycle. In
eukaryotes, DNA replication needs to be tightly regulated in order
to ensure the faithful transmission of the genetic material to the
daughter cells. To this end, a process called licensing controls the
timely initiation of DNA replication, ensuring that only after
passage through mitosis the chromatin becomes competent for a
new round of replication. Cdt1 regulates replication licensing by
controlling the recruitment of Mini-Chromosome Maintenance
proteins (MCMs) onto origins of replication [1–3]. Cdt1 is
specifically expressed during the G1 phase of the cell cycle [4–8]
and its function is regulated by multiple independent mechanisms;
binding to the inhibitory protein Geminin [6,9], and degradation
through Cdk-SCF
Skp2 [10–12] and Cul4A-DDB1
Cdt2 pathway
[13–17]. Overexpression of Cdt1 causes aberrant DNA replication
in different experimental systems [18–21] and human cells [22],
leading to DNA damage and activation of checkpoint pathways
[22,23], while it has been shown that it can also lead to DNA
damage without rereplication in non-transformed and quiescent
cells [24]. Moreover, Cdt1 is overexpressed in different cancers
while recent findings suggest that its expression may participate in
the development of the malignant phenotype [23,25]. Cdt1 is
targeted for degradation in response to different types of DNA
lesions, and this evolutionarily conserved response has been
postulated to constitute an important step in regulating genomic
stability and allowing DNA repair [26,27,28]. Cdt1 proteolysis
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34621requires ubiquitination by the Cul4A-DDB1 ubiquitin ligase and
takes place independently of the classic DDR pathway mediated
by ATM/ATR and CHK1/CHK2 kinases [15,16,26,27]. Cdt1
ubiquitination has been shown to require interaction with PCNA
[14,15,16,29,30,31] and the DCAF protein (DDB1- and CUL4-
associated factor) Cdt2 [14,17,28,32,33]. Whereas Cdt1 targeting
for degradation in response to UV and c-irradiation is relatively
well understood, little is known about Cdt1 proteolytic degrada-
tion in cells treated with commonly used chemotherapeutic
anticancer agents, which target DNA. These drugs are among
the most effective in clinical practice and have produced
significant increases in the survival of patients with cancer when
used in combination with drugs that have different mechanisms of
actions. However, they show significant limitations, since many
patients with cancer either do not respond to the treatment, or
develop resistance. In addition, some DNA-damaging agents are
toxic and have only a limited therapeutic window. The
identification of new cellular targets will help understand the
requirements for efficient responses by different types of cancer
cells and will provide information for a better understanding of the
chemotherapeutic drug’s cellular mechanisms of action.
Here we analyze the effect of anticancer agents of the four main
classes of DNA targeting chemotherapeutic drugs [34], the
alkylating agent methyl methane sulphonate (MMS), cisplatin
that forms various DNA adducts, the anti-metabolite 5-FU, the
topoisomerase inhibitors etoposide and doxorubicin on targeting
the replication factor Cdt1 in different human cancerous cell lines.
Results
UV irradiation and alkylating agents target Cdt1 for
degradation
Cdt1 was previously shown to be targeted for proteolysis
following UV treatment of HeLa cells [15,26,27,37]. In accor-
dance with these studies we show that UV irradiation in HeLa
cells promotes a rapid Cdt1 degradation within 30 minutes after
the induction of the damage which persists up to 6 hours
(Figure 1A). Cdt1 degradation was triggered even at low doses
of UV irradiation (2 J/m
2) as depicted by immunofluorescence
(Figure 1B) and was reversed in the presence of the proteasome
inhibitor MG-132 suggesting that UV-induced Cdt1 targeting for
degradation depends on proteasome activity (Figure 1A).
In order to investigate whether routinely used anticancer
chemotherapeutic agents activate the Cdt1 proteolysis similar to
UV, anticancer agents with distinct mechanisms of action were
screenedfortheirabilitytotargetthelicensingfactorCdt1indifferent
human cancerous cell lines. We first examined whether Cdt1
targeting occurs in response to cisplatin known to introduce DNA
adducts that mainly result in intrastrand cross-links. HeLa cells were
incubated with increasing concentrations of cisplatin and 6 hours
upon treatment Cdt1 protein levels were assessed by western blotting
(Figure 2A). Cisplatin treatment induces a pronounced reduction of
Cdt1 protein levels (Figure 2A, lanes 2–4, left panel), while Geminin
protein expression remains unaltered (Figure 2A, left panel). In
addition, treatment of HeLa cells with 10, 50 and 100 mg/ml of
cisplatin did not result in activation of the apoptotic pathway, as
indicated by the intact PARP protein, while PARP cleavage became
detectable only in the high concentrations (100 mg/ml) (Figure 2A,
left panel). HeLa cells treated in addition to cisplatin with the
proteasome inhibitor MG-132 show stabilization of the Cdt1 protein
expression (Figure 2A, left panel, lanes 5–8). Similar results were
observed when the human hepatocellular liver carcinoma cell line
HepG2, was treated with cisplatin, suggesting that cisplatin targets
Cdt1 for proteolysis in both cell lines (Figure 2A, right panel).
We then examined whether treatment of HeLa cells with the
alkylating agent MMS leads to Cdt1 protein degradation similarly
to cisplatin. HeLa cells were treated with increasing concentrations
of the specific agent for 3 hours (Figure 2B, left panel) and its
protein levels were assessed by western blot. As shown in Figure 2B,
Cdt1 is targeted for degradation in response to MMS treatment
(lanes 1–3). Similar to what was observed upon UV-irradiation
and cisplatin treatment, Cdt1 targeting was proteolysis-dependent,
as indicated by the stabilization of Cdt1 protein levels in cells co-
treated with the proteasome inhibitor MG-132 (lanes 4–6). A
similar effect of MMS treatment on Cdt1 targeting for degradation
was observed in HepG2 cells incubated with the same concentra-
tions of MMS, suggesting common ways of regulation in both cell
types (Figure 2B, right panel).
In order to assess whether Cdt1 downregulation in response to
DNA-damage takes place in cells in the G1 phase of the cell cycle,
we employed double immunofluorescence analysis in an asyn-
chronous population of HeLa cells using the expression profile of
cyclin A as a specific marker of cells in S, G2 and early M phase of
the cell cycle [38]. As shown in Figure 2C and previously reported
[4,7,15], Cdt1 is expressed specifically in cells in G1 phase and
thus its expression is mutually exclusive with cyclin A. Treatment
of the cells with either cisplatin or MMS leads to degradation of
Cdt1 and absence of Cdt1-specific fluorescent signal, while the
Figure 1. UV irradiation of HeLa cells promotes rapid Cdt1
degradation. (A) HeLa cells were irradiated with 20 and 50 J/m
2 UV
and cells were analyzed after 0.5, 1, 3 and 6 hours. In addition, cells
were cultured in the presence of the proteasome inhibitor MG-132 for
2 hr and then irradiated with 50 J/m
2 UV. Total protein extracts were
prepared and subjected to western blot analysis using antibodies
against Cdt1. Cdc2 was used as a loading control. (B) HeLa cells were
irradiated with 2, 5 and 10 J/m
2 UV and incubated for 1 hour. Cells were
fixed and stained with anti-Cdt1 (green) and anti-CPDs (red) antibodies.
DNA was counterstained with DAPI (blue). Scale bars: B, 50 mm.
doi:10.1371/journal.pone.0034621.g001
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(Figure 2C, D). These data suggest that Cdt1 degradation upon
cisplatin and MMS treatment takes place in cells in G1 phase and
is cyclin A-independent. Similar results were obtained in cisplatin-
treated synchronized in G1-phase HeLa cells (data not shown). We
conclude that cisplatin and MMS lead to proteolysis of Cdt1 in
different cancer cells.
Differential regulation of Cdt1 in response to different
topoisomerase II inhibitors
We next investigated whether Cdt1 targeting for degradation
occurs in response to chemotherapeutic agents that promote DNA
damage by interfering with the function of topoisomerase II, such
as Doxorubicin and etoposide. To this end, HeLa cells were
incubated with increasing concentrations of Doxorubicin for
6 hours and western blot analysis was used to assess Cdt1 protein
expression levels (Figure 3A). As shown in Figure 3A (left panel),
treatment of cells with 0.2, 2 and 10 mM of Doxorubicin resulted
in a mild decrease in Cdt1 protein levels while Geminin levels
were unaffected (Figure 3A, lanes 2–4). The decrease of Cdt1
protein levels in response to doxorubicin was more profound in
doxorubicin-treated HepG2 cells (Figure 3A, lanes 10–12). In both
cell lines, co-treatment with the proteasome inhibitor MG-132
resulted in the stabilization of Cdt1 protein levels, implying a
Figure 2. Cdt1 is targeted for proteolysis in response to DNA damage caused by Cisplatin and MMS. HeLa and HepG2 cells were
cultured in the presence of Cisplatin (10, 50 and 100 mg/ml) for 6 h (lanes 1–4 and 9–12) or (B) MMS (150 and 600 mM) for 3 h (lanes 1–3 and 7–9) and
in the presence of MG-132 (20 mM) (+MG-132) (lanes 5–8 and 13–16 (A) and lanes 4–7 and 10–12 (B)). Cellular protein extracts were prepared and
western blot analysis was performed using antibodies against Cdt1, PARP, Geminin and Tubulin as a loading control. (C) HeLa cells cultured in
absence or in presence of Cisplatin (50 mg/ml) or MMS (150 mM) were subjected to immunofluorescence analysis using antibodies against Cdt1 and
Cyclin A, whereas DNA was stained with DAPI. (D) Percentage of HeLa cells expressing Cdt1 or CyclinA after Cisplatin or MMS treatment. Scale bars: C,
50 mm.
doi:10.1371/journal.pone.0034621.g002
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14–16).
Subsequently, HeLa cells were treated with increased amounts
of the topoisomerase-II inhibitor etoposide for 6 h and western
blot was used to determine Cdt1 protein levels. Cdt1 stability
appeared unaffected in HeLa cells treated with etoposide even in
high drug concentrations which were able to activate the apoptotic
pathway as judged by PARP cleavage (Figure 3B, left panel).
However, Cdt1 was profoundly degraded in HepG2 cells treated
with etoposide in concentrations that are not efficient to promote
apoptosis (Figure 3B, right panel), suggesting a distinct regulation
of Cdt1 targeting in response to etoposide treatment between these
cell lines (Figure 3B, lanes 5–6).
To investigate in greater detail the observed differential
regulation of Cdt1 in response to doxorubicin and etoposide
excluding specific cell phase interfering, we assessed the effect of
these drugs in Cdt1 stability in cells in the G1 phase of the cell
cycle. Since an immunofluorescence-based examination was not
possible due to the natural fluorescence of doxorubicin, we
synchronized cells in the G1 phase as it is described in materials
and methods, while the efficacy of synchronization was tested by
immunofluorescence using antibodies against Cdt1 and Cyclin A
(data not shown). As shown in Figure 3C, while treatment of
synchronized HeLa and HepG2 cells with Doxorubicin resulted in
a mild downregulation of Cdt1 at the concentration of 2 mM
(Figure 3C, lanes 5 and 10), treatment of HeLa cells with
Etoposide does not affect Cdt1 protein levels (Figure 3C, lanes 2,
3). In contrast Cdt1 stability is affected in HepG2 cells in the G1
phase treated with etoposide as shown in Figure 3C (lanes 7, 8).
5-Fluouracil and Tamoxifen do not promote Cdt1
degradation
To address a possible effect of the chemotherapeutic agent 5-FU
on Cdt1 targeting upon DNA damage, HeLa cells were treated
Figure 3. Differential regulation of Cdt1 in response to the topoisomerase inhibitors Doxorubicin and Etoposide. HeLa and HepG2
cells were treated for 6 h with (A) Doxorubicin (0.2, 2 and 10 mM) (Doxo) or (B) Etoposide (20 and 80 mM) (Etopo), in the presence or absence of the
proteasome inhibitor MG-132 (+MG-132). Total protein extracts were prepared and subjected to western blot analysis using antibodies against Cdt1,
PARP, Geminin and Tubulin. (C) HeLa and HepG2 cells were synchronized in M phase with nocodazole, and subsequently were incubated with
Etoposide (20 and 80 mM) (lanes 2–3, 7–8) or Doxorubicin (0.2 and 2 mM) (lanes 4–5, 9–10). Protein extracts were subjected to Western blot analysis
using antibodies against Cdt1 and Tubulin.
doi:10.1371/journal.pone.0034621.g003
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asssesed by western blotting. As shown in Figure 4, (lanes 2–4) no
alteration of Cdt1 protein levels upon 5-FU treatment was
observed. On the contrary, incubation of 5-FU in HepG2 cells
resulted in a mild downregulation of Cdt1 expression (Figure 4,
lanes 10–11), which was proteolysis-dependent as revealed by
stabilization of Cdt1 protein levels in MG-132 treated cells
(Figure 4, lanes 13–14). In addition, in accordance with previous
results, Geminin protein levels remained unaffected.
To further investigate Cdt1 regulation upon 5-FU treatment,
the effect of the drug on Cdt1 levels was tested by co-
immunolocalisation with cyclin A. An asynchronous population
of HeLa cells was treated with 5-FU and double immunofluores-
cence using antibodies against Cdt1 and Cyclin A was performed
(Figure 5A, left panel). In accordance with our previous results,
treatment of HeLa cells with 5-FU had no effect on the stability of
Cdt1 protein (Figure 5A, left panel and 5B). The percentage of the
cells expressing cyclin A was not altered after 5-FU treatment,
suggesting that the drug does not arrest cell cycle progression
(Figure 5B). In order to mark the percentage of cells undergoing
active replication in the presence or absence of 5-FU, HeLa cells
were pulsed with the thymidine analogue BrdU which incorpo-
rates into DNA during S phase, combined with different
concentrations of 5-FU (Figure 5A, right panel). As shown in
Figure 5B, the percentage of cells undergoing DNA replication
was not altered in the presence of 5-FU, indicating that treatment
with 5-FU does not affect the cell cycle profile.
In contrast, the percentage of cells expressing Cdt1 was reduced
in HepG2 cells treated with 5-FU by 20% (Figure 5C left panel
and 5D). Interestingly, the percentage of the cells expressing cyclin
A was increased by approximately 15% (Figure 5C and 5D).
Moreover, the percentage of cells incorporating BrdU was also
augmented by 15% in HepG2 cells treated with 5-FU (Figure 5C,
right panel and 5D), indicating that treatment with 5-FU in this
cell line leads to an accumulation of cells in S-phase, where Cdt1 is
not expressed.
To investigate the 5-FU effect on Cdt1 targeting in HeLa and
HepG2 cells in greater detail, we synchronized both cell lines in
G1 phase of the cell cycle and assessed Cdt1 protein levels after
treatment with 5-FU. As shown in Figure 5E, Cdt1 protein levels
were not affected in synchronized in G1 phase HeLa and HepG2
cells treated with 5-FU, indicating that this drug does not interfere
with Cdt1 protein stability.
These data suggest that different chemotherapeutic agents that
induced DNA damage show differential response on Cdt1
targeting for proteolysis. To explore the effect of a chemothera-
peutic drug that does not induce DNA damage on Cdt1 stability,
we treated HeLa and HepG2 cells with increased concentrations
of the estrogen antagonist Tamoxifen (Tam). As illustrated in
Figure 6, Cdt1 protein expression remains unaffected after Tam
treatment in both HeLa and HepG2 cells, suggesting that Cdt1
degradation is regulated by chemotherapeutic agents that induce
DNA damage only.
Cdt1 degradation in response to chemotherapeutic
agents depends on PCNA
Previous studies revealed that Cdt1 targeting for proteolysis
upon DNA damage requires the ubiquitin ligase Cul4A-Ddb1
Cdt2
and interaction with PCNA [14,15,16,28,29,30,32]. To investigate
whether the same pathway targets Cdt1 for degradation in
response to DNA damage caused by the drugs used in this study,
we silenced PCNA expression using siRNA technology. As shown
in Figure 7, knock-down of PCNA expression in HeLa cells treated
with MMS leads to a corresponding rescue of Cdt1 degradation
compared to siRNA for Luciferase –MMS-treated cells (compare
lanes 1 and 2). These results indicate that PCNA is required for
Cdt1 degradation upon DNA damage caused by MMS.
Discussion
One of the current approaches to modern cancer treatment is to
identify cancer-specific molecular targets against which drugs can
be developed. However, cancer is a highly complex disease,
showing genetic variability not only between different cancer
types, but also between patients having the same cancer type and
even different cells within the same tumour. The diversity of
cancer calls for identification of drugs aiming against multiple
targets to ensure efficient responses by different types of cancer
cells. In addition, discovering new cellular targets of the commonly
used chemotherapeutic agents will help understanding their
cellular mechanisms of action. Here we explore the effects of
anticancer agents with distinct mechanisms of action on the
targeting of the replication factor Cdt1 in different human
cancerous cell lines, simulating the effect of these drugs in the
activation of Cdt1-dependent checkpoint in different cancer types.
Cisplatin is a platinum-based drug that distorts the structure of
the DNA duplex, activating the NER (Nucleotide Excision Repair)
pathways, the major pathway responsible for the removal of
cisplatin–DNA adducts. The treatment with cisplatin activates cell
cycle checkpoints through the activation of ATM/ATR and the
downstream Chk2 and Chk1 kinases [39] and modulates several
signal transduction pathways such as the AKT (v-akt murine
thymoma viral oncogene homologue) pathway, c-ABL (v-abl
Abelson murine leukaemia viral oncogene homologue 1), p53,
MAPK (mitogen-activated protein kinase)/JNK (c-Jun NH2-
terminal kinase)/ERK (extracellular signal-regulated kinase),
pathways which interfere with cisplatin’s cytotoxicity [reviewed
in [40]]. Here, we show that Cdt1 is targeted for proteolysis-
dependent degradation in response to cisplatin, in both the
cervical carcinoma cell line HeLa and the hepatoma cell line
HepG2, suggesting that this drug is able to activate the Cdt1-
dependent checkpoint in different cancer cells. Interestingly, while
cisplatin induces checkpoint activation through the ATM/ATR
pathway, Cdt1 degradation in response to DNA damage is ATM/
ATR-independent [26].
Topoisomerase II (TOP2) is the target of several important
classes of anticancer drugs, including the epipodophyllotoxin
Figure 4. 5-Fluoruracil (5-FU) does alter Cdt1 protein expres-
sion levels in HepG2 but not in HeLa cells. HeLa and HepG2 cells
were incubated for 6 h with 5-FU (0.1, 10 and 100 mg/ml) in the absence
(lanes 1–4 and 9–10) or in the presence (lanes 5–8 and 12–14) of MG-
132 (20 mM). Protein extracts were analyzed by Western blotting using
antibodies against Cdt1, PARP, Geminin and Tubulin.
doi:10.1371/journal.pone.0034621.g004
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e34621Figure 5. Treatment with 5-Fluoruracil (5-FU) doesn’t alter Cdt1 protein expression levels in HeLa or HepG2 cells. Asynchronous HeLa
(A) and HepG2 cells (C) were incubated with 5-FU (0.1 and 100 mg/ml) in the presence of BrdU (20 mM, for 1 h). Cells were subjected to
immunofluorescence using antibodies against Cdt1, Cyclin A and BrdU. DNA was visualized with DAPI or Hoechst 3258. The percentage of HeLa (B)
and HepG2 (D) cells expressing Cdt1, Cyclin A and BrdU in presence of 5-FU, 0.1 mg/ml (grey columns), 100 mg/ml (black columns) and control cells
(white columns) is shown; Data are the mean values of the quantifications from at least 3 different experiments from each condition and represent
mean 6 SD. **p,0.01, ***p,0.001. (E) HeLa and HepG2 cells were synchronized with nocodazole, released to enter G1 phase, and incubated with
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are highly active anticancer agents in many different clinical
settings, we asked whether the replication protein Cdt1 is targeted
for degradation upon treatment. Surprisingly, Cdt1 shows
differential regulation in response to the different topoisomerase
II poisons. The treatment of both HeLa and HepG2 cells with
doxorubicin results in the activation of the Cdt1-dependent
checkpoint, although this targeting was less pronounced than
following cisplatin treatment. Similarly, etoposide treatment results
in Cdt1 degradation in HepG2 cells. In contrast, Cdt1 is not
targeted in HeLa cells treated with etoposide, suggesting a
differential Cdt1 targeting after treatment with different topo2
drugs and between different cell lines. Interestingly, doxorubicin
and etoposide belong to different Topoisomerase II poison
categories in respect to their ability to intercalate or not to
DNA. Doxorubicin is able to intercalate to DNA and notably has a
range of effects on cells, in addition to inhibition of TOP2, such as
to production of free radicals, membrane damage and induction of
protein–DNA crosslinks [41]. In contrast, etoposide belongs to
non-intercalating Topo2 poisons believed to induce damage
through protein–drug interactions that have key roles in the
ability of TOP2 poisons to trap TOP2 covalent complexes [42,43].
The cell-type specificity following etoposide treatment may be
dependent on a cell-type specific ability of the poison to trap
TOP2 covalent complexes or may reflect cell type specific
differences in the cell cycle machinery and/or the repair pathways.
Our data suggest that etoposide and doxorubicin could be used in
a combinatorial antitumorigenic therapy in order to effectively
target Cdt1 degradation and this chemotherapeutic scheme might
target more efficiently cell proliferation of different cell types.
Our results indicate that Cdt1 degradation in response to
chemotherapeutic agents takes place in G1 phase of the cell cycle
and is cyclinA-independent [15,26]. We would therefore antici-
pate that agents that act in different phases of the cell cycle would
not affect Cdt1 stability upon genotoxic stress. Indeed, the
treatment of cells with the pyrimidine nucleotide analogue 5-
Fluoruracil (5-FU), which as an antimetabolite drug directly affects
the supply of dNTPs to replicative polymerases and thus acts
during S phase of the cell cycle, did not induce Cdt1 degradation
in both synchronized in G1 phase HeLa and HepG2 cells. In
support of this, Cdt1 was targeted for degradation in response to
the alkylating agent MMS and the platinum-based drug cisplatin,
which modify the DNA structure and induce DNA damage during
all the phases of the cell cycle, including G1.
The estrogen receptor antagonist Tamoxifen, widely used as a
chemotherapeutic drug for breast cancer, does not induce DNA
damage. As expected, in cells treated with Tamoxifen, Cdt1 was
not targeted for degradation, indicating that Cdt1 proteolysis is
activated specifically upon DNA damage by chemotherapeutic
drugs that act in G1.
Previous studies suggest that the Cdt1 degradation pathway
upon DNA damage induced by UV and ionizing radiation
requires direct interaction with PCNA and ubiquitination by the
Cul4A-Ddb1
Cdt2 ubiquitin ligase [13,15,16,26,27,30]. Whether
the same pathway targets Cdt1 in response to chemotherapeutic
anticancer agents is not known. Our experiments of knocking
down the expression of PCNA using siRNA suggest that PCNA is
required for the degradation of Cdt1 in response to MMS,
indicating that similar mechanisms to preserve genomic integrity
in response to different insults.
Cdt1 expression is increased in colon and non-small-cell lung
carcinomas [25,44,45]. Moreover, Cdt1 overexpression has been
linked with increased tumor growth values, aneuploidy and worst
prognosis of non-small-cell lung carcinomas patients when
combined with mutations in p53 [25,45]. This is in accordance
with experiments that show that Cdt1 expressing cells formed
tumors in nude mice and furthermore transgenic mice that
5-FU (10 and 100 mg/ml) for 6 hours. Total cell lysates were extracted and subjected to Western blot analysis using antibodies against Cdt1 and
Tubulin. Scale bars: A, C, 50 mm.
doi:10.1371/journal.pone.0034621.g005
Figure 6. Treatment with Tamoxifen does not affect Cdt1
protein expression levels. HeLa and HepG2 cells were treated with
Tamoxifen (0.2, 2 and 10 mM) for 6 h, in absence (lanes 1–4, 9–11) or in
presence (lanes 5–8, 12–14) of MG-132. Cells were harvested, protein
extracts were prepared and subjected to Western blot analysis using
antibodies against Cdt1 and Tubulin as a loading control.
doi:10.1371/journal.pone.0034621.g006
Figure 7. PCNA is involved in the Cdt1 proteolysis pathway.
HeLa cells were transfected with 100 nM siRNAs for PCNA (PCNA RNAi)
and Luciferase (Lucifer. RNAi) for 72 h. Subsequently, cells were either
uncultured or cultured in the presence of MMS (600 mM) (lanes 1–3) for
3 h before cell lysis. Total cell lysates were prepared and analyzed by
Western blot using antibodies against PCNA, Cdt1, and Tubulin.
doi:10.1371/journal.pone.0034621.g007
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lymphomas when crossed with p53 null mice [46,47]. Moreover
Liontos et al., have suggested that Cdt1 overexpression could play
a role in cancer development as its overexpression can occur early
in premalignant states and participate in tumor development [23].
Recent studies in cancer biology have revealed a rare population
of cells that can be found in tumors, have stem cell-like properties,
survive after drug treatment or surgical removal of the tumor, and
can reinitiate the tumor [48,49]. Several studies have tried to shed
light on the biology of these cancer stem cells [50,51], but still they
are only poorly understood. Since these cells are actively
replicating cells, anticancer agents that induce the degradation
of the licensing factor Cdt1 could be used in order to specifically
eliminate this cell population.
In conclusion, our study suggests that genotoxic therapies used
routinely against cancer differentially affect Cdt1-dependent
degradation and consequently licensing regulation. Information
about the specific cellular targets in response to distinct anticancer
chemotherapeutic drugs in different cancer cell types will
contribute to the optimization of the efficacy of chemotherapy
through a more accurate classification and a better understanding
of their mechanism of action. Combining the best chemothera-
peutic action with specific targets in cellular pathways offers a
powerful new approach to cancer treatment that might counteract
the many ways that human cells can become drug-resistant, while
Cdt1 targeting might be per se essential as a factor promoting
tumor development.
Materials and Methods
Cell culture and DNA damage induction
HeLa and HepG2 cells (ATCC) were cultured in Dulbecco’s
Modified Eagle’s (DMEM) medium (GIBCO) with 10% (v/v)
Fetal Bovine Serum (GIBCO), 1% (v/v) penicillin/streptomycin
(GIBCO) at 37uC and 5% CO2 atmosphere. Subconfluent HeLa
and HepG2 cell cultures were incubated with Methyl Methane
Sulfonate (MMS, Aldrich Chem. Co.) for 3 h, and the
chemotherapeutic agents Cisplatin [cis-diamminedichloroplatinu-
m(II), CDDP], Doxorubicin Hydrochloride, 5-Fluorouracil, Eto-
poside and Tamoxifen at the indicated concentrations for 3 h. The
chemotherapeutic drugs were purchased from Sigma and
prepared from stock solutions in dimethyl sulfoxide (DMSO),
except MMS which was prepared from stock solution in sterile
H2O. Where indicated, cells were incubated with 20 mM MG-132
(Calbiochem) for 3 h before the end of drug treatment. UV-
irradiation was carried out at 2–50 J/m
2 using a Stratalinker.
Cell synchronization
To synchronize HeLa cells in mitosis, exponentially growing
cells were treated with 5 ng/ml Nocodazole (Sigma) for 16 h [35].
Mitotic cells were collected by shake-off in cold PBS, washed twice
in PBS, and further cultured for 2–3 hours in complete DMEM
without nocodazole, so as to proceed in G1 phase before drug
treatment. The same protocol was followed for synchronizing
HepG2 cells.
Western blotting
Total cell lysates, prepared by lysing cell pellets directly in SDS-
page loading buffer, were subjected to electrophoresis in 6%
acrylamide gels for Cdt1 and PARP, 10% for PCNA and 15% for
Geminin and transferred to PVDF membranes (Millipore).
Immunodetection was performed using affinity purified polyclonal
antibodies against Cdt1 (1:2.000) [4] and Geminin (1:2.000) [7],
PARP (BD Pharmigen, 1:2.000), and monoclonal anti-tubulin
(Sigma, 1:20.000), anti-PCNA (Santa Cruz Biotechnology,
1:500)and anti-Cdc2 (1:5.000) [15].
Immunofluorescence
For immunofluorescence, cells were grown on glass slides and after
drug treatment or UV irradiation they were fixed in 4% formaldehyde
for 10 min, washed twice with PBS, permeabilized with 0.3%
TritonX-100 in PBS and then washed three times with PBS. Cells
were treated with blocking buffer (3% BSA, 10% fetal bovine serum in
PBS) for 1 hour and incubated with primary antibodies overnight in a
wet chamber. Cells were washed in PBS containing 0.1% Tween
three times and incubated for 1 h with fluorescently labeled secondary
antibodies, Alexa-Fluor-568 goat anti-mouse IgG and Alexa-Fluor-
488 goat anti-mouse IgG. After washing, DNA was stained with DAPI
(Vector Laboratories). Polyclonal antibodies used against Cdt1 (1:600)
and Geminin (1:1500) were previously described [4,7,36], and
monoclonal anti-Cyclin A (Neomarkers, 1:40). Thymidine dimmers
were visualized using an antibody directed against CPDs (Kamiya
Biomedical Company, 1:500).
BrdU staining
Asynchronous growing cells were pulsed with 20 mM BrdU (5-
bromo-2-deoxyuridine) (Sigma) for 1 h followed by fixation in 4%
PFA for 10 min. Then cells were washed twice with PBS,
permeabilized with 0.3% TritonX-100 in PBS and then washed
three times with PBS. DNA was denatured for 1 h with 2 N HCl,
and then cells were washed with 0,1 M Tris-HCl pH 8,8 and
three times with PBS. Cells were treated with blocking buffer (3%
BSA, 10% fetal bovine serum in PBS) for 1 h and incubated with
primary rat anti-BrdU (Oxford Biotechnology, 1:80) overnight in a
wet chamber. Cells were washed in PBS containing 0.1% Tween
three times and incubated with fluorescently labeled secondary
antibody, Alexa-Fluor-568 goat anti-rat IgG. After washing, DNA
was visualized with Hoechst.
RNAi experiments
For RNAi experiments, we used human PCNA siGENOME
SMART pool which was synthesized and obtained from Dharma-
con, Inc., Lafyette. CO. As a control, siRNA for Luciferase
(MWG, Biotech) was used. HeLa cells were plated in 30 mm dish
and transfected with 100 nM siRNA on the following day (when
cells were 30% confluent) using DharmaFECT, following
DharmaFECT siRNA transfection protocol (Dharmacon, Inc.,
Lafyette. CO). At 72 h post transfection, cells were collected and
protein extracts were analyzed by WB. When indicated, cells were
treated with 600 mM MMS for 3 h and before collecting cells.
Image acquisition and data analysis
Images were acquired with a Nikon Eclipse TE2000-U
microscope and collected with a Nikon Digital Sight DS-L1
camera. All the data presented here are obtained from at least
three different experiments. The results are given as mean 6 SD
and the statistical significance was based on the Student’s t-test,
with *P,0.05, **P,0.01 and ***P,0.001.
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